

*Cont
J2*

specifically binds to human MIF, wherein the human MIF has a molecular weight of approximately 12.5 kDa, and wherein the anti-MIF antibody binds to the 12.5 kDa human MIF.; and

(b) a detectable label, whereby the binding of the antibody in step (a) can be detected.

70. A pharmaceutical composition comprising an anti-MIF antibody or fragment thereof in a suitable pharmaceutical carrier, wherein the MIF has a molecular weight of approximately 12.5 kDa, and wherein the anti-MIF antibody binds to the 12.5 kDa molecular weight human MIF polypeptide.

71. The pharmaceutical composition of claim 70 wherein the anti-MIF antibody is a monoclonal antibody.

72. The pharmaceutical composition of claim 71 wherein the anti-MIF monoclonal antibody is a humanized monoclonal antibody.--

REMARKS


Applicants respectfully request consideration of claims 66-72 of the above-identified patent application to provide for completion of claims supported by the original specification filed on 06 June 1995. The present claims of this divisional patent application provide for subject matter supported in the specification and providing the full scope of the invention as conceived by the inventors. Specifically, support for claims 66-69 relating to a diagnostic immunoassay and kit are found in the specification at page 54-55, and throughout. Moreover, support for claims 70-72 relating to a pharmaceutical composition comprising an anti-MIF antibody is found throughout the specification with therapeutic data of anti-MIF antibody in various predictive models of therapeutic activity. No new matter has been added. Entry of the foregoing amendment is respectfully requested. Claims 66-72 are pending.

Formalities

Applicants have amended the specification to provide an appropriate and current disclosure of the status of the priority patent applications. Applicants have also canceled the Table of Contents to place the specification in better form for issuance. Applicants have further amended the specification and provided additional sequence disclosure pages and an electronic copy to comply with the sequence disclosure requirements. All of the sequence information is found in the specification and the specification is amended to add sequence ID references. The same specification amendments have been made in sibling patent applications. No new matter has been added.

Applicants respectfully request consideration of the claimed invention and examination of pending claims 66-72.

Respectfully submitted,


Jeffrey B. Oster
Attorney for Applicants
Registration No. 32,585

Davis Wright Tremaine
2600 Century Square
1501 Fourth Avenue
Seattle, Washington 98101-1688
Telephone (206) 628 7711
Facsimile (206) 628 7699